Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Cancundude

Rank: Treasurer [?]

Points: 1672 [?]

Votes: 30 Score: 2.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

BearDownAZ

posted on Dec 22, 2020 08:02AM

Very good news Gran Oso. Early bird gets to post first for once. We talked about the possibility DM was stalling on a partnership deal to give time to investigate the new hypothesis. Clearly it's paid off and when you look at the Covid patient population at most risk for death, well as we all know is the same population Apa was originally designed for. The synergies simply don't get much better. What wonderful news indeed.